Radiotherapy developer Eckert & Ziegler reported positive results in the first quarter of 2012 (end-March 30).
Revenues grew 4% to 29.2 million euros ($38 million U.S.), compared to 28.2 million euros ($36.6 million U.S.) in the first quarter of 2011. Profits after taxes were roughly the same as the last four quarters, reaching 2.5 million euros ($3.2 million U.S.).
The company's Isotope Products segment contributed the greatest amount to results, but sales revenues declined by 1% to 14 million euros ($18.2 million U.S.) in the first quarter of 2012.
The firm's Radiation Therapy segment achieved sales growth of 8% in the first quarter to 7.2 million euros ($9.4 million U.S.).
